When Mirimar-based Trinity Health Care Services accepted the overpayments, its CEO was U.S. Rep. Sheila Cherfilus-McCormick, ...

This round, a mix of primary and secondary investments, drew participation from B Capital Group, Banner Health, Danaher ...

Innovaccer has raised a $275M Series F from investors including B Capital Group, Banner Health, Danaher Ventures, Generation ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...

The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...

Truist raised the firm’s price target on Fresenius Medical (FMS) to $25 from $23 and keeps a Hold rating on the shares as ...

Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 7: Primo ...

Fresenius Medical Care (NYSE:FMS – Free Report) had its price target lifted by Truist Financial from $23.00 to $25.00 in a research note published on Monday,Benzinga reports. Truist Financial ...

Investing.com -- Morgan Stanley (NYSE: MS) has upgraded its outlook for the European medical technology sector to "attractive ...

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS – Free Report) in a report released on Friday morning. The brokerage issued a strong-buy rating on the stock. Several ...